Gene News and Research

Latest Gene News and Research

Activated astrocytes could play a harmful role in Alzheimer's disease

A research team composed of University of Kentucky researchers has published a paper which provides the first direct evidence that activated astrocytes could play a harmful role in Alzheimer's disease.

12 Dec 2012

SIRT6 protein may play a critical role in blocking cancer and controlling cellular metabolism

A new study sheds more light on how an anti-aging gene suppresses cancer growth, joint University of Michigan Health System and Harvard Medical School research shows.

11 Dec 2012

GeneTex to introduce new Histone H3 antibody

GeneTex, a leading manufacturer of antibodies and antibody-related reagents, is set to launch a new antibody against phosphorylated Histone H3.

11 Dec 2012

Carbon nanotubes can help regulate chloride levels in nerve cells that contribute to neural injuries

A nanomaterial engineered by researchers at Duke can help regulate chloride levels in nerve cells that contribute to chronic pain, epilepsy, and traumatic brain injury.

11 Dec 2012

Pfizer's PD0325901 experimental drug blocks untreatable NF1 tumors

Researchers conducting a preclinical study in mice successfully used targeted molecular therapy to block mostly untreatable nerve tumors that develop in people with the genetic disorder Neurofibromatosis 1 (NF1).

11 Dec 2012

Weill Cornell research team develops new experimental drug therapy to target DLBCL

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called activated B-cell - DLBCL (ABC-DLBCL), remains a major therapeutic challenge.

11 Dec 2012

uniQure commences acute intermittent porphyria Phase I clinical trial

uniQure B.V., a leader in the field of human gene therapy, today announced the start of its Phase I clinical trial in acute intermittent porphyria (AIP) with the treatment of the first patient.

11 Dec 2012

Quizartinib shows promise against acute myeloid leukemia in Phase II trial

A new drug for patients with acute myeloid leukemia (AML) marked by a specific type of genetic mutation has shown surprising promise in a Phase II clinical trial.

11 Dec 2012

GSK, Fred Hutch to develop therapeutics against facioscapulohumeral muscular dystrophy

Fred Hutchinson Cancer Research Center and GlaxoSmithKline PLC (GSK) today announced a partnership to develop therapeutics to treat an inherited form of muscular dystrophy.

11 Dec 2012

Acetylon announces results from selective HDAC 1/2 inhibitor preclinical study on SCD and bT

Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced results from a preclinical study of a selective histone deacetylase (HDAC) 1/2 inhibitor for the treatment of sickle cell disease (SCD) and beta-thalassemia (bT) at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place in Atlanta, Georgia.

11 Dec 2012

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Celgene International Sàrl today announced that results from a study evaluating the combination of REVLIMID (lenalidomide) plus VIDAZA (azacitidine) in patients 60 years or older with untreated acute myeloid leukemia (AML) were presented at the American Society of Hematology annual meeting in Atlanta, GA.

11 Dec 2012

Boston College professor to research into new drugs that can prevent onset of toxoplasmosis

The American Cancer Society has awarded a four-year, $720,000 grant to Boston College Associate Professor of Biology Marc-Jan Gubbels for research into potential new drugs that can prevent the onset of toxoplasmosis in cancer patients with weakened immune systems.

10 Dec 2012

Immune dysfunction pinpointed in developmental disorder

Children with neurodevelopmental abnormalities resulting from duplication of the methyl-CpG binding protein 2 gene also have impaired T-helper-cell 1 responses, research shows.

10 Dec 2012

RET fusion signals unique NSCLC subtype

The presence of RET fusion genes in approximately 1.5% of non-small-cell lung cancer defines a subset of tumors with distinct clinicopathologic features, research suggests.

10 Dec 2012

FGFR1 amplification heralds poor prognosis in SCCL

Amplification of the fibroblast growth factor receptor 1 gene independently predicts poor outcomes in patients who have undergone resection of squamous cell lung cancer, research shows.

10 Dec 2012

New lung cancer loci found

Genome-wide analysis has identified three new susceptibility loci for lung cancer in a large cohort of never-smoking women in Asia.

10 Dec 2012

New study could help develop anti-inflammatory drugs with fewer side effects

10 Dec 2012

New hope for leukemia patients

Nine of twelve leukemia patients who received infusions of their own T cells after the cells had been genetically engineered to attack the patients' tumors responded to the therapy, which was pioneered by scientists in the Perelman School of Medicine at the University of Pennsylvania

10 Dec 2012

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy significantly extended the lives (overall survival) of people with previously untreated HER2-positive metastatic breast cancer (mBC), compared to Herceptin, chemotherapy and placebo.

10 Dec 2012

Ibrutinib may effectively combat chronic lymphocytic leukemia

The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic lymphocytic leukemia (CLL), according to studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH).

10 Dec 2012

Gene News and Research

Latest Gene News and Research

Activated astrocytes could play a harmful role in Alzheimer's disease

SIRT6 protein may play a critical role in blocking cancer and controlling cellular metabolism

GeneTex to introduce new Histone H3 antibody

Carbon nanotubes can help regulate chloride levels in nerve cells that contribute to neural injuries

Pfizer's PD0325901 experimental drug blocks untreatable NF1 tumors

Weill Cornell research team develops new experimental drug therapy to target DLBCL

uniQure commences acute intermittent porphyria Phase I clinical trial

Quizartinib shows promise against acute myeloid leukemia in Phase II trial

GSK, Fred Hutch to develop therapeutics against facioscapulohumeral muscular dystrophy

Acetylon announces results from selective HDAC 1/2 inhibitor preclinical study on SCD and bT

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Boston College professor to research into new drugs that can prevent onset of toxoplasmosis

Immune dysfunction pinpointed in developmental disorder

RET fusion signals unique NSCLC subtype

FGFR1 amplification heralds poor prognosis in SCCL

New lung cancer loci found

New study could help develop anti-inflammatory drugs with fewer side effects

New hope for leukemia patients

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

Ibrutinib may effectively combat chronic lymphocytic leukemia

eBook: Using iPSCs models for human disease research and drug discovery eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting